Shire PLC (SHP) Lifted to Outperform at BNP Paribas


The brokerage currently has a GBX 5,700 target price on the biopharmaceutical company's stock. BNP Paribas' price objective points to a potential upside of 36.20% from the company's previous close.



from Biotech News